Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Picoplatin in Resistant or Refractory Small Cell Lung Cancer
NCT00116610Phase 2Completed
- Sponsor
- Poniard Pharmaceuticals, Inc.
- Start
- Jun 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of picoplatin in small cell lung cancer (SCLC), sponsored by Poniard Pharmaceuticals, Inc. Primary endpoints: Efficacy at 1 year and Safety at 1 year. Started Jun 2005; status: completed.
02
Drugs
picoplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00116610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116610.